| Summary: | Myeloproliferative disorders, also known as myeloproliferative neoplasms, are stem cell disorders, which encompass a heterogenous group of blood cancers such as chronic myeloid leukemia (CML), essential thrombocythemia (ET), myelofibrosis (MF), polycythemia vera (PV), chronic neutrophilic leukemia, and chronic eosinophilic leukemia. Currently, various pegylated interferons are approved in Canada for the treatment of chronic hepatitis B and C and for the treatment of relapsing remitting multiple sclerosis. None has received a Health Canada Notice of Compliance for an oncology indication. In spite of this, pegylated interferon has been used off-label in Canadian jurisdictions for the treatment of some cancers and some hospitals may choose to provide funding for this treatment. The aim of this report is to summarize and critically appraise the relevant evidence regarding the clinical effectiveness and cost-effectiveness of pegylated interferon alfa 2a (Peg-IFNα-2a) therapy in patients with myeloproliferative disorders
|
|---|